A Systematic Review of Molecular Imaging Agents Targeting Bradykinin B1 and B2 Receptors

• Main Authors: Joseph Lau, Julie Rousseau, Daniel Kwon, François Bénard, Kuo-Shyan Lin
• Format: Article
• Language: English
• Published: MDPI AG 2020-08-01
• Series: Pharmaceuticals
• Subjects: kinins; bradykinin receptors; optical imaging; nuclear imaging; personalized medicine
• Online Access: https://www.mdpi.com/1424-8247/13/8/199

Kinins, bradykinin and kallidin are vasoactive peptides that signal through the bradykinin B1 and B2 receptors (B1R and B2R). B2R is constitutively expressed in healthy tissues and mediates responses such as vasodilation, fluid balance and retention, smooth muscle contraction, and algesia, while B1R is absent in normal tissues and is induced by tissue trauma or inflammation. B2R is activated by kinins, while B1R is activated by kinins that lack the C-terminal arginine residue. Perturbations of the kinin system have been implicated in inflammation, chronic pain, vasculopathy, neuropathy, obesity, diabetes, and cancer. In general, excess activation and signaling of the kinin system lead to a pro-inflammatory state. Depending on the disease context, agonism or antagonism of the bradykinin receptors have been considered as therapeutic options. In this review, we summarize molecular imaging agents targeting these G protein-coupled receptors, including optical and radioactive probes that have been used to interrogate B1R/B2R expression at the cellular and anatomical levels, respectively. Several of these preclinical agents, described herein, have the potential to guide therapeutic interventions for these receptors.